HRS-5632 vs Kylo-11

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: Lipoprotein(a) · full Atherosclerotic Cardiovascular Disease pipeline

HRS-5632

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Atherosclerotic Cardiovascular Diseaseunknown/undisclosed
Weak signal

NCT06732154 · Phase 1 · completed

This is a randomized, blinded, placebo-controlled study, which is a sound design, but the primary measure is adverse-event and safety monitoring rather than a lipid or cardiovascular outcome, and no results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "The percentage of all reported adverse events, serious adverse events and treatment-related adverse events, serious adverse events.". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: April 2027 · NCT07185776 (registry estimate)

No aligned efficacy figure on record for this race.

Kylo-11

Developed by Sino Biopharmaceutical and partners

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHRS-5632Kylo-11
LDL-C, % change—Not reported—Not reported
Non-HDL-C, % change—Not reported—Not reported
ApoB, % change—Not reported—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

HRS-5632
—Not reported
Kylo-11
—Not reported

Non-HDL-C, % change

HRS-5632
—Not reported
Kylo-11
—Not reported

ApoB, % change

HRS-5632
—Not reported
Kylo-11
—Not reported

Lp(a), % change

HRS-5632
—Not reported
Kylo-11
—Not reported

3-point MACE (% with event)

HRS-5632
—Not reported
Kylo-11
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HRS-5632: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Kylo-11: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-5632's landscape · Kylo-11's landscape